Serum Metabolomics Signatures Associated With Ankylosing Spondylitis and TNF Inhibitor Therapy
Ankylosing spondylitis (AS) is a type of spondyloarthropathies, the diagnosis of which is often delayed. The lack of early diagnosis tools often delays the institution of appropriate therapy. This study aimed to investigate the systemic metabolic shifts associated with AS and TNF inhibitors treatmen...
Main Authors: | Jiayong Ou, Min Xiao, Yefei Huang, Liudan Tu, Zena Chen, Shuangyan Cao, Qiujing Wei, Jieruo Gu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-02-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.630791/full |
Similar Items
-
Adalimumab Therapy Restores the Gut Microbiota in Patients With Ankylosing Spondylitis
by: Zena Chen, et al.
Published: (2021-09-01) -
Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs
by: F.M. Perrotta, et al.
Published: (2014-11-01) -
TNF-α inhibitor therapy can improve the immune imbalance of CD4+ T cells and negative regulatory cells but not CD8+ T cells in ankylosing spondylitis
by: Mingcan Yang, et al.
Published: (2020-06-01) -
Coexistence of Ankylosing Spondylitis and Multiple Sclerosis: Trigger with TNF-alpha Antagonist Therapy or Coincidental?
by: Bahar Say, et al.
Published: (2019-09-01) -
Cost of Illness, Quality of Life, and Work Outcomes in Active Ankylosing Spondylitis Patients Treated With Adalimumab in China
by: Liudan Tu, et al.
Published: (2020-11-01)